The same pharmacogenomics that sits on our condition pages, read from the other end. People rarely arrive asking about SLCO1B1 — they arrive having been prescribed a statin. Each page below collects what published guidelines say about one drug, names the genes involved, and links to the variants your own file would contain.
Supplements — kept apart, with the evidence stated on each →
None of this is dosing guidance. Where a clinical guideline exists it is written for prescribers, and the pages say so. Nothing here is a reason to start, stop or change a medication.
An ordinary dosing question, and it sits on the same page as valproate — which is the useful comparison. One level of evidence apart, and a world apart in what it asks a prescriber to do.
CYP2C19
See what the research says → AntiseizureThe strongest kind of finding on this site: not a smaller dose but a drug that must not be given at all. Two mechanisms, seven genes, and neither is visible to a consumer test.
POLG
See what the research says → AntiseizureTwo HLA alleles, two different reactions, and recommendations that name populations rather than applying to everybody. The population part is not a footnote on the guidance — it is the guidance.
HLA-B
See what the research says → AntiseizureTwo genes doing two different jobs on one prescription: one decides how much drug there is, the other decides whether it is safe to start at all.
CYP2C9
See what the research says →The same pharmacogenomics already published on our condition pages, read from the drug side instead: what published guidelines say about one medicine, which genes are involved, and the variants your own file would contain.
No. Where a clinical guideline exists it is written for prescribers, and nothing here is a reason to start, stop or change a medication — that belongs with the clinician or pharmacist managing treatment.
Because almost nothing sold as a supplement has a prescribing guideline behind it the way a drug does, and listing the two together would lend the second the authority of the first.
By gene symbol as a whole word, gathered from the pgx_notes already published on the condition pages that discuss each drug — not a second, separate copy of that information.